Clinicians have called for EGFR gene mutation testing to become a routine part of non-small cell lung cancer (NSCLC) diagnosis after the Therapeutic Goods Administration’s (TGA) approval of oral gefitinib.
Gefitinib, (Iressa) has been approved for patients with locally advanced or metastatic NSCLC whose tumours express activating mutations of the epidermal growth factor- tyrosine kinase (EGFR-TK).
According to a news realease from manufacturer Astra Zeneca, data showed that gefitinib demonstrated significantly longer progression free survival when compared to platinum-containing combination chemotherapy (Hazard ratio [HR] 0.74; 95% confidence interval [CI], 0.65 to 0.85; p<0.0001).
This site is intended for Registered Medical Practitioners.
To make the most of Oncology Update, you need to be logged in.